Histone 2A Family Member J Drives Mesenchymal Transition and Temozolomide Resistance in Glioblastoma Multiforme

Glioblastoma multiforme (GBM) is the most aggressive brain tumor and has a poor prognosis and is poorly sensitive to radiotherapy or temozolomide (TMZ) chemotherapy. Therefore, identifying new biomarkers to predict therapeutic responses of GBM is urgently needed. By using The Cancer Genome Atlas (TC...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hsun-Hua, Lin, Che-Hsuan, Lin, Hui-Yu, Kuei, Chia-Hao, Zheng, Jing-Quan, Wang, Yuan-Hung, Lu, Long-Sheng, Lee, Fei-Peng, Hu, Chaur-Jong, Wu, Dean, Lin, Yuan-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016639/
https://www.ncbi.nlm.nih.gov/pubmed/31906036
http://dx.doi.org/10.3390/cancers12010098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016639/
https://www.ncbi.nlm.nih.gov/pubmed/31906036
http://dx.doi.org/10.3390/cancers12010098

Ejemplares similares